Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs MENEST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (in women at significant risk),Palliative treatment of advanced androgen-dependent carcinoma of the prostate,Palliative treatment of advanced breast cancer in selected postmenopausal women
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
The terminal elimination half-life of conjugated estrogens is approximately 10-24 hours. The half-life of estrone, the primary metabolite, is about 12-18 hours. This supports once-daily dosing.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Conjugated estrogens are metabolized primarily in the liver via hydroxylation and conjugation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2D6) and undergo enterohepatic recirculation.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Estrogens are excreted primarily in urine (about 90-95%) as glucuronide and sulfate conjugates. The remaining 5-10% is excreted in feces via bile. Less than 5% is excreted unchanged.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Estrogens are approximately 50-80% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. Estrone is about 16% bound to SHBG and 80% to albumin; estradiol has higher SHBG affinity.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
The apparent volume of distribution for conjugated estrogens is not well-defined due to tissue binding. For estradiol, Vd is approximately 1.2 L/kg, indicating extensive distribution into tissues and fat.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Oral bioavailability of conjugated estrogens is approximately 40-50% due to first-pass hepatic metabolism. The tablet formulation is designed to deliver a consistent dose; enteric-coated tablets may have slightly different bioavailability.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
No specific dosing adjustment recommended; use with caution in severe renal impairment.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Contraindicated in severe hepatic disease (Child-Pugh class C); for mild to moderate impairment (Child-Pugh A or B), use lowest effective dose and monitor liver function.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Not approved for use in pediatric patients.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Initiate at lowest effective dose (0.3 mg daily) due to increased sensitivity and risk of adverse effects; monitor closely for thromboembolic events and malignancy.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Unopposed estrogen use increases the risk of endometrial hyperplasia and carcinoma. Estrogens should not be used in women with undiagnosed abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Estrogens increase the risk of venous thromboembolism, stroke, and myocardial infarction.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Cardiovascular disorders: increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction,Malignant neoplasms: increased risk of endometrial cancer and possibly breast cancer,Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Visual abnormalities,Dementia risk (when initiated in women >65 years),Jaundice and liver function abnormalities
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Active liver disease or impaired liver function,Known or suspected breast cancer (except in selected metastatic cases),Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer),Active or history of venous thromboembolism,Active or history of arterial thromboembolism (e.g., stroke, MI),Hypersensitivity to estrogens or any ingredient in Menest
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Grapefruit and grapefruit juice may increase serum estrogen levels via CYP3A4 inhibition and should be avoided. High-fat meals may increase absorption; take consistently with or without food. Vitamin C supplements may increase estrogen levels.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associated with fetal genital tract abnormalities, increased risk of spontaneous abortion, and preterm delivery. Estrogens are contraindicated in pregnancy.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Estrogens are excreted in human milk in small amounts. M/P ratio not established. Use during breastfeeding is not recommended as it may reduce milk production and affect infant development.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
No dose adjustments recommended; drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy include increased clearance, but no safe dose established.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Menest (esterified estrogens) contains a mixture of estrogenic substances, primarily sodium estrone sulfate, with lower potency than conjugated equine estrogens (CEE) due to absence of equilin. For vasomotor symptoms, start at lowest effective dose; consider estradiol-based alternatives for better pharmacokinetic profile. Monitor for thromboembolic events; avoid in patients with active liver disease or unexplained vaginal bleeding. Absorption may be impaired in patients with GI malabsorption disorders.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Take with food or milk to reduce gastrointestinal upset.,Report any sudden severe headache, vision changes, chest pain, or leg swelling immediately.,Avoid grapefruit juice and grapefruit products as they may increase estrogen levels.,Do not smoke while using this medication; smoking increases risk of blood clots and stroke.,Inform your physician of any history of breast cancer, uterine cancer, or blood clotting disorders.,Use the lowest effective dose for the shortest duration possible.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs MENEST, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. MENEST is a Estrogen Replacement Therapy that works by Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and MENEST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of MENEST is: 0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and MENEST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. MENEST is classified as Category C. First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.